Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Idera Pharmaceuticals Inc (IDRA) USD0.001

Sell:$2.50 Buy:$2.90 Change: $0.01 (0.37%)
NASDAQ:1.51%
Market closed |  Prices as at close on 25 June 2019 | Switch to live prices |
Sell:$2.50
Buy:$2.90
Change: $0.01 (0.37%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 25 June 2019 | Switch to live prices |
Sell:$2.50
Buy:$2.90
Change: $0.01 (0.37%)
Market closed |  Prices as at close on 25 June 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Contact details

Address:
505 Eagleview Blvd Ste 212
EXTON
19341-1199
United States
Telephone:
+1 (484) 3481600
Website:
www.iderapharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IDRA
ISIN:
US45168K4058
Market cap:
$77.06 million
Shares in issue:
28.02 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Geraghty
    Independent Chairman of the Board
  • Vincent Milano
    President, Chief Executive Officer, Director
  • John Kirby
    Principal Financial Officer and Accounting Officer
  • Bryant Lim
    Senior Vice President, General Counsel, Secretary
  • Robert Fletcher
    Senior Vice President - Business Development and Strategic Planning
  • Joanna Horobin
    Senior Vice President, Chief Medical Officer
  • Robert Doody
    Vice President - Investor Relations and Corporate Communications

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.